My Portfolio
+
LINK YOUR PORTFOLIO

Abivax SA ABVX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:11 PM EDT
89.58quote price arrow up+17.08 (+23.55%)
Volume
5,025,293
52 week range
5.69 - 148.83
Loading...
  • Open81.26
  • Day High92.14
  • Day Low80.77
  • Prev Close72.50
  • 52 Week High148.83
  • 52 Week High Date12/24/25
  • 52 Week Low5.69
  • 52 Week Low Date06/23/25

Latest On Abivax SA

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume3.48M
  • Dividend-
  • Dividend Yield-
  • Beta-

KEY STATS

  • Open81.26
  • Day High92.14
  • Day Low80.77
  • Prev Close72.50
  • 52 Week High148.83
  • 52 Week High Date12/24/25
  • 52 Week Low5.69
  • 52 Week Low Date06/23/25
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume3.48M
  • Dividend-
  • Dividend Yield-
  • Beta-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date09/10/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine...
Sylvie Gregoire Pharm.D.
Chairwoman of the Board
Marc De Garidel
Chief Executive Officer
Didier Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Jerome Denis Ph.D.
Executive Vice President - Process Development & Manufacturing
Address
7-11 Boulevard Haussmann
Paris
75009
France